RxDoctor Payments Data

Ramit Sharma, MD

Pulmonary Disease · Phoenix, AZNPI 1659374593

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 45 manufacturers reported payments, led by United Therapeutics Corporation at 30.1% of the total. Reporting peaked in 2019 at $20,633 and has fallen 81.9% since, to $3,740 in 2024. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$64,543in general payments, 2019–2025

Across 1,107 payments — averaging $58.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$19K
  • Bayer$16K
  • Mylan Specialty L.p.$12K
  • GSK$3K
  • AstraZeneca$3K
  • Genentech USA, Inc.$2K
  • plus $10K from 39 others

What the payments were for

  • Consulting fees$7,59412%
  • Speaking & faculty fees$36,51257%
  • Travel & lodging$1890%
  • Food & beverage$19,84931%
  • Education$3991%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,543 in reported general payments places this provider in the 90th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$210,317
Medicare patients
613
Services billed
2,844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan83$1,063,365
AdempasRiociguat40$551,356
UptraviSelexipag18$322,386
OfevNintedanib Esylate18$234,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter132$125,755
Breztri AerosphereBudesonide/Glycopyr/Formoterol54$42,912
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$32,446
Breo ElliptaFluticasone/Vilanterol66$30,909
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$21,810
Spiriva RespimatTiotropium Bromide15$13,119
SymbicortBudesonide/Formoterol Fumarate33$11,470
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$5,842
Albuterol Sulfate HfaAlbuterol Sulfate183$5,673
Azelastine-FluticasoneAzelastine/Fluticasone24$2,597
Ventolin HfaAlbuterol Sulfate20$1,758

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$1,253$1,385,751101 claims
BayerAdempas$15,660$551,35640 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,050$279,98179 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,012$178,474230 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,863$54,38287 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →